Cargando…

The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012

INTRODUCTION: The English Department of Health introduced universal MRSA screening of admissions to English hospitals in 2010. It commissioned a national audit to review implementation, impact on patient management, admission prevalence and extra yield of MRSA identified compared to “high-risk” spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuller, Christopher, Robotham, Julie, Savage, Joanne, Hopkins, Susan, Deeny, Sarah R., Stone, Sheldon, Cookson, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772122/
https://www.ncbi.nlm.nih.gov/pubmed/24069282
http://dx.doi.org/10.1371/journal.pone.0074219
_version_ 1782284289140850688
author Fuller, Christopher
Robotham, Julie
Savage, Joanne
Hopkins, Susan
Deeny, Sarah R.
Stone, Sheldon
Cookson, Barry
author_facet Fuller, Christopher
Robotham, Julie
Savage, Joanne
Hopkins, Susan
Deeny, Sarah R.
Stone, Sheldon
Cookson, Barry
author_sort Fuller, Christopher
collection PubMed
description INTRODUCTION: The English Department of Health introduced universal MRSA screening of admissions to English hospitals in 2010. It commissioned a national audit to review implementation, impact on patient management, admission prevalence and extra yield of MRSA identified compared to “high-risk” specialty or “checklist-activated” screening (CLAS) of patients with MRSA risk factors. METHODS: National audit May 2011. Questionnaires to infection control teams in all English NHS acute trusts, requesting number patients admitted and screened, new or previously known MRSA; MRSA point prevalence; screening and isolation policies; individual risk factors and patient management for all new MRSA patients and random sample of negatives. RESULTS: 144/167 (86.2%) trusts responded. Individual patient data for 760 new MRSA patients and 951 negatives. 61% of emergency admissions (median 67.3%), 81% (median 59.4%) electives and 47% (median 41.4%) day-cases were screened. MRSA admission prevalence: 1% (median 0.9%) emergencies, 0.6% (median 0.4%) electives, 0.4% (median 0%) day-cases. Approximately 50% all MRSA identified was new. Inpatient MRSA point prevalence: 3.3% (median 2.9%). 104 (77%) trusts pre-emptively isolated patients with previous MRSA, 63 (35%) pre-emptively isolated admissions to “high-risk” specialties; 7 (5%) used PCR routinely. Mean time to MRSA positive result: 2.87 days (±1.33); 37% (219/596) newly identified MRSA patients discharged before result available; 55% remainder (205/376) isolated post-result. In an average trust, CLAS would reduce screening by 50%, identifying 81% of all MRSA. “High risk” specialty screening would reduce screening by 89%, identifying 9% of MRSA. CONCLUSIONS: Implementation of universal screening was poor. Admission prevalence (new cases) was low. CLAS reduced screening effort for minor decreases in identification, but implementation may prove difficult. Cost effectiveness of this and other policies, awaits evaluation by transmission dynamic economic modelling, using data from this audit. Until then trusts should seek to improve implementation of current policy and use of isolation facilities.
format Online
Article
Text
id pubmed-3772122
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37721222013-09-25 The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012 Fuller, Christopher Robotham, Julie Savage, Joanne Hopkins, Susan Deeny, Sarah R. Stone, Sheldon Cookson, Barry PLoS One Research Article INTRODUCTION: The English Department of Health introduced universal MRSA screening of admissions to English hospitals in 2010. It commissioned a national audit to review implementation, impact on patient management, admission prevalence and extra yield of MRSA identified compared to “high-risk” specialty or “checklist-activated” screening (CLAS) of patients with MRSA risk factors. METHODS: National audit May 2011. Questionnaires to infection control teams in all English NHS acute trusts, requesting number patients admitted and screened, new or previously known MRSA; MRSA point prevalence; screening and isolation policies; individual risk factors and patient management for all new MRSA patients and random sample of negatives. RESULTS: 144/167 (86.2%) trusts responded. Individual patient data for 760 new MRSA patients and 951 negatives. 61% of emergency admissions (median 67.3%), 81% (median 59.4%) electives and 47% (median 41.4%) day-cases were screened. MRSA admission prevalence: 1% (median 0.9%) emergencies, 0.6% (median 0.4%) electives, 0.4% (median 0%) day-cases. Approximately 50% all MRSA identified was new. Inpatient MRSA point prevalence: 3.3% (median 2.9%). 104 (77%) trusts pre-emptively isolated patients with previous MRSA, 63 (35%) pre-emptively isolated admissions to “high-risk” specialties; 7 (5%) used PCR routinely. Mean time to MRSA positive result: 2.87 days (±1.33); 37% (219/596) newly identified MRSA patients discharged before result available; 55% remainder (205/376) isolated post-result. In an average trust, CLAS would reduce screening by 50%, identifying 81% of all MRSA. “High risk” specialty screening would reduce screening by 89%, identifying 9% of MRSA. CONCLUSIONS: Implementation of universal screening was poor. Admission prevalence (new cases) was low. CLAS reduced screening effort for minor decreases in identification, but implementation may prove difficult. Cost effectiveness of this and other policies, awaits evaluation by transmission dynamic economic modelling, using data from this audit. Until then trusts should seek to improve implementation of current policy and use of isolation facilities. Public Library of Science 2013-09-12 /pmc/articles/PMC3772122/ /pubmed/24069282 http://dx.doi.org/10.1371/journal.pone.0074219 Text en © 2013 Fuller et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fuller, Christopher
Robotham, Julie
Savage, Joanne
Hopkins, Susan
Deeny, Sarah R.
Stone, Sheldon
Cookson, Barry
The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012
title The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012
title_full The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012
title_fullStr The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012
title_full_unstemmed The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012
title_short The National One Week Prevalence Audit of Universal Meticillin-Resistant Staphylococcus aureus (MRSA) Admission Screening 2012
title_sort national one week prevalence audit of universal meticillin-resistant staphylococcus aureus (mrsa) admission screening 2012
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772122/
https://www.ncbi.nlm.nih.gov/pubmed/24069282
http://dx.doi.org/10.1371/journal.pone.0074219
work_keys_str_mv AT fullerchristopher thenationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT robothamjulie thenationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT savagejoanne thenationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT hopkinssusan thenationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT deenysarahr thenationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT stonesheldon thenationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT cooksonbarry thenationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT fullerchristopher nationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT robothamjulie nationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT savagejoanne nationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT hopkinssusan nationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT deenysarahr nationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT stonesheldon nationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012
AT cooksonbarry nationaloneweekprevalenceauditofuniversalmeticillinresistantstaphylococcusaureusmrsaadmissionscreening2012